201 – 250 of 341
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios : better diagnostic markers of Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Serum neurofilament light protein predicts clinical outcome in traumatic brain injury
(
- Contribution to journal › Article
-
Mark
Plasma β-amyloid in Alzheimer's disease and vascular disease
(
- Contribution to journal › Article
-
Mark
Preclinical amyloid-β and axonal degeneration pathology in delirium
(
- Contribution to journal › Article
-
Mark
Plasma tau in Alzheimer disease
(
- Contribution to journal › Article
- 2015
-
Mark
Amyloid biomarkers in Alzheimer's disease.
(
- Contribution to journal › Scientific review
-
Mark
Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease : A prospective 9-year study
(
- Contribution to journal › Article
-
Mark
Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function.
(
- Contribution to journal › Article
-
Mark
An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics-Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
(
- Contribution to journal › Article
-
Mark
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls
(
- Contribution to journal › Article
-
Mark
Increased CSF biomarkers of angiogenesis in Parkinson disease.
(
- Contribution to journal › Article
-
Mark
CSF biomarkers for the differential diagnosis of Alzheimer's disease. A large-scale international multicenter study.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
(
- Contribution to journal › Article
-
Mark
Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study.
2015) In Alzheimer's & Dementia(
- Contribution to journal › Article
-
Mark
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
(
- Contribution to journal › Article
- 2014
-
Mark
Monitoring of β-amyloid dynamics after human traumatic brain injury
(
- Contribution to journal › Article
-
Mark
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography.
(
- Contribution to journal › Article
-
Mark
SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival.
(
- Contribution to journal › Article
-
Mark
Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease.
(
- Contribution to journal › Article
-
Mark
The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?
(
- Contribution to journal › Article
- 2013
-
Mark
Fluid biomarkers in Alzheimer's disease - current concepts
(
- Contribution to journal › Scientific review
-
Mark
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
(
- Contribution to journal › Article
-
Mark
Functional Mannose-Binding Lectin Haplotype Variants are Associated with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Plasma tau levels in Alzheimer's disease
(
- Contribution to journal › Letter
-
Mark
Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
(
- Contribution to journal › Article
-
Mark
Evaluating Amyloid-beta Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Diagnostic Power of 24S-Hydroxycholesterol in Cerebrospinal Fluid: Candidate Marker of Brain Health
(
- Contribution to journal › Article
-
Mark
Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
A beta 1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter Study
(
- Contribution to journal › Article
-
Mark
Complement Gene Single Nucleotide Polymorphisms and Biomarker Endophenotypes of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of A beta(38), A beta(40), and A beta(42) in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls
(
- Contribution to journal › Article
-
Mark
Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia
(
- Contribution to journal › Article
-
Mark
Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia
(
- Contribution to journal › Article
-
Mark
Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
(
- Contribution to journal › Article
- 2012
-
Mark
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
(
- Contribution to journal › Article
-
Mark
Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Profiles of Amyloid beta-Related Biomarkers in Alzheimer's Disease
(
- Contribution to journal › Article